Glioblastoma Multiforme Clinical Trials

60 recruiting

Glioblastoma Multiforme Trials at a Glance

87 actively recruiting trials for glioblastoma multiforme are listed on ClinicalTrialsFinder across 6 cities in 23 countries. The largest study group is Phase 1 with 38 trials, with the heaviest enrollment activity in Boston, New York, and Houston. Lead sponsors running glioblastoma multiforme studies include Northwell Health, Jasper Gerritsen, and Institute of Cancer Research, United Kingdom.

Browse glioblastoma multiforme trials by phase

Treatments under study

About Glioblastoma Multiforme Clinical Trials

Looking for clinical trials for Glioblastoma Multiforme? There are currently 60 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Glioblastoma Multiforme trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Glioblastoma Multiforme clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 87 trials

Recruiting
Phase 1

A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM

Glioblastoma MultiformeRecurrent Glioblastoma
Boston Scientific Corporation36 enrolled9 locationsNCT05303467
Recruiting
Phase 2

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

Central Nervous System DiseasesBrain CancerGlioblastoma Multiforme (GBM)+4 more
Black Diamond Therapeutics, Inc.162 enrolled4 locationsNCT07326566
Recruiting
Phase 1

A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma

GlioblastomaGliomaGlioblastoma Multiforme of Brain
Tetragon Biosciences Ltd30 enrolled3 locationsNCT07464925
Recruiting
Phase 1

Sonodynamic Therapy in Patients With Recurrent GBM

GBMGlioblastoma MultiformeRecurrent Glioblastoma
Shayan Moosa, MD11 enrolled1 locationNCT06039709
Recruiting
Phase 1Phase 2

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

Cervical CancerMelanomaBladder Cancer+6 more
University of Arizona30 enrolled2 locationsNCT06814496
Recruiting
Not Applicable

NK Cell Therapy for Malignant Solid Brain Tumors

Brain MetastasisGlioblastoma Multiforme (GBM)Glioblastoma (GBM)+2 more
Peking University Third Hospital27 enrolled4 locationsNCT07552233
Recruiting
Phase 2

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

Metastatic Brain TumorGlioblastomaGlioblastoma Multiforme+7 more
Nationwide Children's Hospital120 enrolled21 locationsNCT05843253
Recruiting
Phase 1

Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc

Glioblastoma Multiforme
UNC Lineberger Comprehensive Cancer Center36 enrolled1 locationNCT05366179
Recruiting

Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma Multiforme

Glioblastoma Multiforme
National Cancer Institute (NCI)200 enrolled1 locationNCT00083512
Recruiting
Phase 3

Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma

GlioblastomaNeoplastic DiseaseGlioblastoma (GBM)+3 more
Telix Pharmaceuticals (Innovations) Pty Limited50 enrolled4 locationsNCT07100730
Recruiting
Not Applicable

Application of FET-PET in Fusion With MRI in the Treatment of Glioblastoma Multiforme [TYR-GLIO]

Glioblastoma Multiforme
Copernicus Memorial Hospital189 enrolled1 locationNCT06466031
Recruiting
Phase 1

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

NeoplasmsNeoplasms by SiteBrain Diseases+30 more
M.D. Anderson Cancer Center24 enrolled3 locationsNCT03911388
Recruiting
Phase 1Phase 2

Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)

NeoplasmsBrain TumorGlioblastoma+3 more
NaviFUS Corporation10 enrolled1 locationNCT06329570
Recruiting
Phase 3

A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients

NeoplasmsBrain TumorGlioblastoma+5 more
NaviFUS Corporation32 enrolled2 locationsNCT06496971
Recruiting

Targeted Pediatric High-Grade Glioma Therapy

Metastatic Brain TumorGlioblastomaGlioblastoma Multiforme+6 more
Nationwide Children's Hospital350 enrolled21 locationsNCT05839379
Recruiting
Phase 1Phase 2

HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM

Glioblastoma MultiformeAstrocytoma, Grade III
David Baskin MD62 enrolled1 locationNCT03596086
Recruiting
Phase 1Phase 2

Early Phase Study of KESONOTIDE™in Participants With Solid Tumours

Breast CancerLung CancersOvarian Cancer+4 more
Filamon LTD80 enrolled3 locationsNCT06926075
Recruiting
Early Phase 1

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

GlioblastomaGlioblastoma MultiformeHigh Grade Glioma+6 more
Nationwide Children's Hospital15 enrolled18 locationsNCT06333899
Recruiting
Not Applicable

WBSI Guided Personalized Delivery of TTFields

GBMTumor, BrainGlioma Glioblastoma Multiforme
Abramson Cancer Center at Penn Medicine155 enrolled2 locationsNCT05086497
Recruiting
Phase 1Phase 2

Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma

Glioblastoma Multiforme
Neonc Technologies, Inc.49 enrolled12 locationsNCT02704858